Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.71 |
| ▸ | KDM5C | P41229 | 6/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.71 |
| ▸ | KDM4A | O75164 | 5/20 | 0.71 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.71 |
| ▸ | KDM3A | Q9Y4C1 | 4/20 | 0.71 |
| ▸ | KDM6B | O15054 | 3/20 | 0.71 |
| ▸ | KMO | O15229 | 2/20 | 0.63 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.59 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.56 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.56 |
| ▸ | KDM4B | O94953 | 1/20 | 0.56 |
| ▸ | KDM5A | P29375 | 3/20 | 0.55 |
| ▸ | TET3 | O43151 | 1/20 | 0.55 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ASPH | Q12797 | 1/20 | 0.55 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.55 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541336 | 1.00 | KDM4C (0.71) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL3737328 | 0.98 | KDM4C (0.69) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| Nitrous Acid SCHEMBL28651257 | 0.93 | KDM4C (0.63) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL27717106 | 0.90 | KMO (0.73) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL23303939 | 0.88 | KMO (0.67) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL30318846 | 0.88 | KMO (0.67) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL1759899 | 0.87 | KMO (0.61) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL31466644 | 0.86 | KMO (0.71) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL4251799 | 0.86 | KMO (0.71) | KDM4CKDM5CKDM4EKDM4AKDM2A | |
| SCHEMBL29407015 | 0.86 | KDM4C (0.78) | KDM4CKDM5CKDM4EKDM4AKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| CN-118745147-A | Cobalt-catalyzed method for preparing isonicotinic acid compound by taking carbon dioxide as carboxyl source | 南开大学 | 2024-10-08 | — | — | CN | disclosed |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | ALMAC DISCOVERY LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117430549-A | Method for preparing isonicotinic acid compound by taking carbon dioxide as carboxyl source | 南开大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-116589401-A | Near-infrared ratio fluorescent probe and application thereof | 山东大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-111393362-B | Crystalline calcium-based microporous framework material and preparation method thereof | 上海烟草集团有限责任公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-113712964-B | Application of 9,10 dihydrophenanthrene compound in preparation of coronavirus 3CL protease inhibitor | 上海中医药大学 | 2023-04-07 | — | — | CN | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1322309-A4 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1322309-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002049993-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | USP19, USP18, UBE2I | KDM4C 782/4885KDM5C 751/4885KDM4E 710/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | KDM4C 4732/4885KDM5C 4397/4885KDM4E 4661/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | KDM4C 2547/4885KDM5C 3995/4885KDM4E 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.